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Abstract
Background: Breast cancer is the most common cancer and the leading cause of cancer related
deaths in women worldwide. The incidence of the disease is increasing globally and this increase is
occurring at a faster rate in population groups that hirtherto enjoyed low incidence. This study was
designed to evaluate the role of a simple tandem repeat polymorphism (STRP) in the aromatase
(CYP19) gene in breast cancer susceptibility in Nigerian women, a population of indigenous sub-
Saharan African ancestry.
Methods: A case-control study recruiting 250 women with breast cancer and 250 women without
the disease from four University Teaching Hospitals in Southern Nigeria was carried out between
September 2002 and April 2004. Participants were recruited from the surgical outpatient clinics
and surgical wards of the Nigerian institutions. A polymerase chain reaction (PCR)-based assay was
employed for genotyping and product sizes were detected with an ABI 3730 DNA Analyzer.
Results: Conditional logistic regression analysis revealed that harboring the putative high risk
genotypes conferred a 29% increased risk of breast cancer when all women in the study were
considered (Odds ratio [OR] = 1.29, 95% confidence interval [CI] 0.83–2.00), although this
association was not statistically significant. Subgroup analysis based on menopausal status showed
similar results among premenopausal women (OR = 1.35, 95% CI 0.76–2.41 and postmenopausal
women (OR = 1.27, 95% CI 0.64–2.49). The data also demonstrated marked differences in the
distribution of (TTTA)n repeats in Nigerian women compared with other populations.
Conclusion: This study has shown that harboring 10 or more repeats of the microsatellite
(TTTA)n repeats of the CYY19 gene is associated with a modest increased risk of breast cancer in
Nigerian women.
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Background
An aging world population with rising global burden of
breast cancer [1], emerging evidence suggesting that post-
menopausal obesity as well as weight gain over the adult
years are positively associated with postmenopausal breast
cancer [2] and the finding that breast cancer patients may
have an inherently higher aromatase expression in breast
adipose tissue when compared to healthy women [3] have
increased research interest on mechanisms underlying aro-
matase action in breast carcinogenesis.
The CYP19 gene encodes aromatase, which is responsible
for the rate-limiting step in the metabolism of C19 ster-
oids to estrogens and is expressed in most breast carcino-
mas [4]. Five different polymorphisms in the CYP19 gene
have been described in relationship to breast cancer risk,
including the highly polymorphic tetranucleotide repeats
in intron 5 [5-9], a C-T substitution in the 3' noncoding
region of exon 10 [10], a cytosine to thymine substitution
in codon 264 of exon 7 (resulting in amino acid Arginine
to Cysteine substitution) [11], a silent G-A polymorphism
at codon 80 in exon 3 [6], and a rare 3 base pair change
within the promoter region of exon 1.4 [9]. Although the
tetranucleotide repeat polymorphism is the most widely
studied of all these variants in the CYP19 gene, there are a
lot of inconsistencies in reports in various populations
with respect to breast cancer susceptibility [5-9]. There is
evidence suggesting that part of the population differ-
ences in breast cancer risk may be related to the wide racial
variation in the distribution of various polymorphisms in
different populations. This study was designed to evaluate
the role of the tetranucleotide repeat polymorphism in




A total of 500 study participants comprising 250 women
with breast cancer and 250 age-matched control women
without the disease were recruited from four University
Teaching Hospitals located in Southeastern and Midwest-
ern Nigeria, including University of Benin Teaching Hos-
pital, Benin City; University of Nigeria Teaching Hospital,
Enugu; Nnamdi Azikiwe University Teaching Hospital,
Nnewi; and University of Port Harcourt Teaching Hospi-
tal, Port Harcourt. Recruitment was carried out between
September 2002 and April, 2004. The study protocol was
approved by the Ethics and Research Committees of the
participating Nigerian Institutions and the Institutional
Review Board of the University of Pittsburgh.
Written informed consent was obtained from participants
willing to participate in the study prior to commencement
of recruitment. At the end of the questionnaire session,
anthropometric measurements including height, weight,
waist and hip circumferences were taken.
Biological samples
Biological samples including 40 milliliters of blood in
two 15-milliliter plain vacutainer tubes and one 10 mil-
liliter K3-EDTA tube were collected at the end of the ques-
tionnaire session. Samples were centrifuged within 10 h
of collection; buffy coat was separated from plasma and
red cells in the K3-EDTA vacutainer tubes and carefully
aliquoted into 3 ml tubes while clots separated from
serum in the plain vacutainer tubes were turned into two
20 ml plain tubes and stored at -20°C in each of the Nige-
rian study sites until transferred in ice packs to the Nige-
rian coordinating center at the University of Benin
Teaching Hospital where samples were stored at -20°C
until transferred to the University of Pittsburgh in dry ice
packs. Samples were then stored at -80°C at the University
of Pittsburgh until DNA extraction.
DNA extraction
DNA was extracted from buffy coats using the QIAamp
Mini Kit protocol (Qiagen, Chatsworth, CA) or blood
clots using the QIAamp Midi Kit protocol (Qiagen, Chats-
worth, CA) for participants in whom buffy coat was una-
vailable. The DNA was stored at 4°C until amplified by
polymerase chain reaction (PCR) and used for genotyping
on the ABI 3730 DNA Analyzer (Applied Biosystems, Fos-
ter City, CA).
PCR and genotyping
PCR amplification of the polymorphic fragment was gen-
erated using primers, 5'-CAA CTC GAC CCT TCT TTA TG-
3' (forward) and 5'-GTT TGA CTC CGT GTG TTT GA-3'
(reverse). The forward primer was 5'-labeled with a fluo-
rescent dye (FAM, 5-carboxy-flouorescein) for automated
fragment analysis. A 50 µl reaction mixture containing 2
µl of genomic DNA, 8 µl of deoxynuclotide triphosphates,
0.5 µl each of forward and reverse primers, 5 µl of 10×
buffer, 1.5 µl of MgCl and 2 µl of Taq polymerase was
placed in Thermalcycler (MJ Dyad PCR machine). After
denaturing for 5 min at 95°C, the DNA was amplified for
35 cycles at 95°C for 30 s, 55°C for 30 s, 72°C for 45 s,
followed by a 5 min extension at 72°C. A positive control
containing genomic DNA and a negative control contain-
ing everything except DNA were included in the PCR
experiment. Five µl of each PCR product, including the
controls, were run on a 1% agarose gel to ensure that the
expected fragment size was generated.
The product sizes were then detected with an ABI 3730
DNA Analyzer (Applied Biosystems, Foster City, CA) at the
Genomics and Proteomics Core Laboratory at the Univer-
sity of Pittsburgh. Allele calling was carried out using Gen-
otyper software (Applied Biosystems, Foster City, CA).Journal of Carcinogenesis 2006, 5:12 http://www.carcinogenesis.com/content/5/1/12
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Statistical analysis
Data analysis was carried out using Statistical Analysis
Software (SAS), Version 8.0. Association between demo-
graphic, reproductive and anthropometric variables and
breast cancer risk was first assessed using conditional
logistic regression. Each matched case was paired with the
corresponding control to enable differences between the
cases and controls to be calculated. First each variable was
assessed alone in a univariate model. The strength of sig-
nificant variables was further assessed by building multi-
variate models.
Conditional logistic regression was also used to assess the
relationship between the distribution of the genotypes of
the CYP19 tetranucleotide (TTTA)n repeats and breast can-
cer risk. Based on information available in the literature,
the CYP19 genotypes were categorized into two groups for
the purpose of conditional logistic regression. There is evi-
dence suggesting that an increased risk of breast cancer is
associated with 10 or more (TTTA)n repeats. Genotypes
containing at least one allele with 10 or more repeats were
categorized as high risk genotypes while genotypes con-
taining alleles with less than 10 repeats were categorized
as low risk genotypes. Because of the small number of
individuals carrying these genotypes, we had to collapse
all genotypes in the high risk category as one group in the
logistic regression model. A multivariate conditional
logistic regression model containing the significant pre-
dictors of breast cancer risk in the descriptive analysis and
the CYP19 genotype data was then developed to assess
gene environment interactions.
Results
Association of demographic/reproductive characteristics 
with breast cancer risk
Conditional logistic regression analysis was used to exam-
ine the association between demographic/reproductive
variables of study participants and breast cancer risk. In
the final multiple conditional logistic regression model,
only family history of breast cancer (OR = 8.07, 95% CI
1.003–64.95), waist/hip ratio (WHR) (OR = 1.98, 95% CI
1.27–3.10), age at first full term pregnancy (OR = 1.31,
95% CI 1.01–1.71), and higher level of education (OR =
1.33, 95% CI 1.05–1.74) were found to be significant pre-
dictors of breast cancer risk.
Distribution of CYP19 (TTTA)n repeat alleles
All women
Seven different alleles (designated A1 to A7, as shown in
Table 1) of the tetranucleotide (TTTA)n repeat polymor-
phism of the CYP19 gene were identified in 228 cases and
228 control subjects in whom polymerase chain reaction
(PCR) amplification and genotyping were successful. The
most common alleles were A1 (356 base pairs [bp], 7
repeats) and A2 (360 bp, 8 repeats) alleles. The A1 allele
was slightly more common in the cases (allele frequency
0.3385) than in the control subjects (allele frequency
0.3026) while allele A2 was less common in the cases
(allele frequency 0.4978) compared to the control sub-
jects (allele frequency 0.5504) as shown in Table 1. The
distribution of these alleles was not significantly modified
by menopausal status.
Distribution of CYP19 (TTTA)n repeat polymorphism 
genotypes
All women
The distribution of the various genotypes of the CYP19
(TTTA)n  repeat polymorphism are shown in Table 2.
Homozygosity for the A1 (7 repeats) allele was more com-
mon in the cases (27 [11.84%]) than in the control sub-
jects (19 [8.33%]) while homozygosity for the A2 (8
repeats) allele was less common in the cases (59
[25.89%]) compared to the control subjects (65
[28.51%). Heterozygosity for the A1 and A2 alleles (A1A2
genotype) was less common in the cases (73 [32.02%])
compared to the control subjects (83 [36.40%]). Other
less common genotypes are as shown in Table 2.
Premenopausal women
The distribution of the CYP19 (TTTA) genotypes in pre-
menopausal women is similar to the general pattern seen
in all women. The most common genotypes include A1A2
(44 [34.92%] in cases, 50 [38.76%] in controls), and
A2A2 (31 [24.60%] in cases, 36 [27.91%] in controls) as
shown in Table 3.
Table 1: Allele distribution of the polymorphic CYP19 in breast cancer cases and controls: number of alleles (allele frequency)
Allele type Cases Controls
Number (Frequency) Number (Frequency)
A1 (356) 7 repeats 152 (0.3385) 144 (0.3026)
A2 (360) 8 repeats 228 (0.4978) 251 (0.5504)
A3 (364) 9 repeats 13 (0.0310) 15 (0.0329)
A4 (368) 11 repeats 2 (0.0088) 0 (0.0000)
A5 (376) 12 repeats 38 (0.0819) 31 (0.0724)
A6 (380) 13 repeats 19 (0.0240) 17 (0.0395)
A7 (384) 14 repeats 0 (0.0000) 1 (0.0022)Journal of Carcinogenesis 2006, 5:12 http://www.carcinogenesis.com/content/5/1/12
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Postmenopausal women
Of 108 postmenopausal breast cancer cases and 108 age-
matched control subjects in the study, PCR amplification
and genotyping was successful in 102 cases and 99 con-
trols. As shown in Table 4, the A1A2 genotype was slightly
less common in the cases (29 [28.43%] compared to the
control subjects (33 [33.33%]) while the A2A2 genotype
was almost equally distributed among the cases (28
[27.45%]) and controls (29 [29.29%]).
Association of CYP19 (TTTA)n genotypes and breast 
cancer risk
Conditional logistic regression was used to evaluate the
association between the distribution of the CYP19
(TTTA)n genotypes and breast cancer risk. For the purpose
of this analysis, the genotypes were categorized into two
broad groups; genotypes with at least one allele contain-
ing 10 or more (TTTA)n repeats were classified as high-risk
genotypes while those containing less than ten alleles
were considered as low-risk genotypes. This classification
was adopted based on evidence in the literature suggest-
Table 3: (TTTA)n repeat polymorphism genotype in breast cancer cases and controls (Premenopausal women)
Genotype Cases Controls
Number (n) Percentage (%) Number (n) Percentage (%)
A1A1 (356/356) 17 13.49 9 6.98
A1A2 (356/360) 44 34.92 50 38.76
A1A3 (356/364) 2 1.59 3 2.33
A1A4 (356/368) 1 0.79 0 0.00
A1A5 (356/376) 8 6.35 5 3.88
A1A6 (356/380) 2 1.59 5 3.88
A2A2 (360/360) 31 24.60 36 27.91
A2A3 (360/364) 2 1.59 5 3.88
A2A4 (360/368) 1 0.79 0 0.00
A2A5 (360/376) 11 8.73 10 7.75
A2A6 (360/380) 5 3.97 5 3.88
A4A4 (368/368) 1 0.79 0 0.00
A5A5 (376/376) 1 0.79 1 0.79
Totals 126 100.00 129 100.00
Risk associated with at least one allele containing 10 or more repeats: OR = 1.35, 95% CI 0.76–2.41
Table 2: (TTTA)n repeat polymorphism genotype in breast cancer cases and controls (All women)
Genotype Cases Controls
Number (n) Percentage (%) Number (n) Percentage (%)
A1A1 (356/356) 27 11.84 19 8.33
A1A2 (356/360) 73 32.02 83 36.40
A1A3 (356/364) 7 3.07 6 2.63
A1A4 (356/368) 1 0.44 0 0.00
A1A5 (356/376) 11 4.82 9 3.95
A1A6 (356/380) 6 2.63 4 1.75
A2A2 (360/360) 59 25.89 65 28.51
A2A3 (360/364) 4 1.75 7 3.07
A2A4 (360/368) 1 0.44 0 0.00
A2A5 (360/376) 21 9.21 18 7.89
A2A6 (360/380) 12 5.26 11 4.82
A2A7 (360/384) 0 0.00 1 0.44
A3A3 (364/364) 1 0.44 1 0.44
A3A5 (364/376) 1 0.44 0 0.00
A4A4 (368/368) 1 0.44 0 0.00
A5A5 (376/376) 3 1.32 2 0.88
A5A6 (376/380) 0 0.00 2 0.88
Total 228 100.00 228 100.00
Risk associated with at least one allele containing 10 or more repeats: OR = 1.29, 95% CI 0.83–2.00
Risk associated with homozygosity for alleles containing 10 or more repeats: OR = 4.00, 95% CI 0.45–35.79Journal of Carcinogenesis 2006, 5:12 http://www.carcinogenesis.com/content/5/1/12
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ing that the higher number of repeats (10 and 12 repeats)
were associated with increased risk of breast cancer. Con-
ditional logistic regression analysis showed a 29%
increased risk of breast cancer for harboring at least one
high risk allele [[10] or more (TTTA)n repeats] when all
women were considered (0R = 1.29, 95% CI 0.83–2.00).
There was a 35% increased risk of premenopausal breast
cancer for women harboring at least one high risk allele
(OR = 1.35, 95% CI 0.76–2.41). Harboring the high risk
genotype was associated with a 27% increased risk of
postmenopausal breast cancer (0R = 1.27, 95% CI 0.64–
2.49).
The risk profile of women homozygous for any of the high
risk alleles was further considered. Four breast cancer
cases were homozygous for any of the high risk alleles;
three of these women carried the homozygous A5A5 gen-
otype while one was homozygous for the A4A4 [[10]
(TTTA)n  repeats]. Two control participants were
homozygous for any of the high risk alleles. When all
women were considered together, there was a 4-fold
increased risk of breast cancer for women carrying the
homozygous genotypes of any of the high risk alleles
although this was not statistically significant (OR = 4.00,
95% CI 0.45–35.79). There was a 2-fold increased risk of
postmenopausal breast cancer (OR = 2.00, 95% CI 0.18–
22.05) for carriers of the homozygous genotypes.
Discussion
This study has demonstrated marked variation in the dis-
tribution of the tetranucleotide (TTTA)n repeats of the
CYP19 (aromatase) gene among Nigerian women com-
pared with other population groups. The (TTTA)n repeats
ranged from seven to 14 repeats with seven and eight
repeats constituting the major alleles with allele frequen-
cies of 0.3385 and 0.3026 for the seven repeat allele in the
cases and controls respectively and 0.4978 and 0.5504 for
the eight repeat allele in cases and controls respectively.
Among some Caucasian population groups, the seven
repeat allele appears to be the most common, with allele
frequency of 0.484 in the Nordic population [5] and 0.50
in non-Latina Whites in Southern California [9]. In the
British population, the six repeat allele appears to be the
most common (allele frequency of 0.379) [8] with the
seven repeat allele frequency of 0.021. A much higher fre-
quency of 0.76 was reported for the seven repeat allele
among African American women in southern California
[9]. Populations of Japanese descent appear to harbor the
highest frequency of the seven repeat allele (allele fre-
quency of 0.85) among Japanese Americans in Southern
California and Hawaii [9].
Our data suggest that harboring at least one 10 or more
repeats was associated with a 29% increased risk of breast
cancer (OR = 1.29, 95% CI 0.83–2.00) and this risk pro-
file was unaltered in premenopausal (OR = 1.35, 95% CI
0.76–2.41) and postmenopausal women (OR = 1.27,
95% CI 0.64–2.49). It is important to note that four of the
six study participants that harbored the homozygous var-
iants of the putative high risk alleles were cases. Although
not statistically significant, probably due to the small
number of cases with these homozygous genotypes, there
was a 4-fold increased risk of breast cancer in women who
were homozygous for these alleles (OR = 4.00, 95% CI
0.45–35.79). Controlling for other significant reproduc-
tive and lifestyle factors identified in our study subjects
Table 4: (TTTA)n repeat polymorphism genotype in breast cancer cases and controls (Postmenopausal women)
Genotype Cases Controls
Number (n) Percentage (%) Number (n) Percentage (%)
A1A1 (356/356) 10 9.90 10 10.10
A1A2 (356/360) 29 28.43 33 33.33
A1A3 (356/364) 5 4.90 3 3.03
A1A5 (356/376) 3 2.94 4 4.04
A1A6 (356/380) 4 3.92 0 0.00
A2A2 (360/360) 28 27.45 29 29.29
A2A3 (360/364) 2 1.96 2 2.02
A2A5 (360/376) 10 9.80 7 7.07
A2A6 (360/380) 7 6.86 6 6.06
A2A7 (360/384) 0 0.00 1 1.01
A3A3 (364/364) 1 0.98 1 1.01
A3A5 (364/376) 1 0.98 0 0.00
A5A5 (376/376) 2 1.96 1 1.01
A5A6 (376/380) 0 0.00 2 2.02
Totals 102 100.00 99 100.00
Risk associated with at least one allele containing 10 or more repeats: OR = 1.27, 95% CI 0.64–2.49
Risk associated with homozygosity for alleles containing 10 or more repeats: OR = 2.00, 95% CI 0.18–22.05Journal of Carcinogenesis 2006, 5:12 http://www.carcinogenesis.com/content/5/1/12
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did not alter the risk profile. Our analyses was based on
the speculation that harboring longer repeat lengths of the
CYP19 tetranucleotide repeat polymorphism will increase
the risk of breast cancer. This consideration was based on
evidence from previous epidemiological studies demon-
strating increased risk of breast cancer with longer repeat
lengths of the tetranucleotide repeats.
Our findings of increased breast cancer risk in association
with harboring longer repeats of the (TTTA)n tetranucle-
otide repeats have been noted in other populations. Kris-
tensen et al [5], studied the association between the
tetranucleotide simple tandem repeat polymorphism and
breast cancer risk in a case-control study (sporadic cases:
n = 182; familial cases: n = 185; and controls; n = 252)
among Norwegian and Swedish individuals and observed
a positive association between carriage of the 12 repeat
allele [allele [12], (TTTA)12] of CYP19 and risk of breast
cancer compared with repeat lengths less than 12 (OR =
2.42, 95% CI, 1.03–5.80). These authors also observed a
higher frequency of the 12 allele among estrogen- and
progesterone receptor positive cases compared with recep-
tor negative cases [5]. Using data from the Nurses' Health
Study, Haiman et al [7] examined the relationship
between the CYP19 tetranucleotide repeats and breast
cancer risk among US Caucasian women; the authors
found that harboring the 10 repeat allele [not identified in
the Nordic population by Kristensen et al [5]] conferred a
3-fold increased risk of breast cancer (OR = 3.08, 95% CI
1.35–7.01). A non-significant 49% increased risk was also
reported by these investigators for individuals harboring
the 12 repeat allele (OR = 1.49, 95% CI 0.86–2.56). In a
study among Caucasian women in the US, Siegelmann-
Danieli and Buetow [6] observed a lower frequency of the
12 allele and higher frequency of the 7 allele among cases
(n = 348) than controls (n = 145).
Other studies have not provided support for the associa-
tion between CYP19 repeat alleles and breast cancer risk.
In a multiethnic study [cases/controls: African-American
(71/104); Japanese (10/41); Latina (61/99); and non-
Latina White (49/66)], Probst-Hensch et al [9], observed
equivalent allele (7, 7 (-3 bp), 8, 10, 11, 12, 13) and gen-
otype frequencies among breast cancer cases and controls
in all ethnic groups. Likewise, Healey et al [8] observed no
relationship between either the 10 or 12 repeat alleles and
breast cancer risk among British subjects.
Differences in study size and ethnicity may account for the
discrepancy between study results. The studies of Siegel-
mann-Danieli and Buetow [6] and Probst-Hensch et al
[9], had less than 200 Caucasian cases and/or controls,
which may result in unreliable allele frequency estimates
for rare alleles. The positive association reported by Kris-
tensen et al [5] was observed among Caucasian women of
Scandinavian ancestry. High risk CYP19 alleles may be
linked to functional genetic variations among specific
Caucasian ethnic groups. Consequently, disproportionate
frequencies of different Caucasian ancestral groups
between cases and controls may influence associations
between CYP19 alleles and disease risk.
Because of the weak association detected in most associa-
tion studies involving single nucleotide polymophisms
and breast cancer risk, haplotype-based studies have been
proposed as a more powerful comprehensive approach to
identify causal genetic variation underlying breast cancer
and other complex diseases. Employing these techniques
using data from the Multiethnic Cohort (MEC) Study
recruiting African-American, Hawaiian, Japanese, Latina
and white women, Haiman et al [12] utilized twenty-five
haplotype-tagging SNPs (htSNPs) to predict the common
haplotypes with high probability within the CYP19 gene
and genotyped these htSNPs in a breast cancer case-con-
trol study nested in the MEC Study (cases, n = 1355; con-
trols, n = 2580). These investigators observed significant
haplotype-effects in block 2 [P = 0.01; haplotypes 2b (OR
= 1.23; 95% CI, 1.07–1.40), 2d (OR = 1.28; 95% CI, 1.01–
1.62)]. They also found a common long-range haplotype
comprising block-specific haplotypes 2b and 3c to be
associated with increased risk of breast cancer (haplotype
2b-3c: OR = 1.31; 95% CI, 1.11–1.54). Although this
methodology does not require the casual variant to be
identified and tested directly, it has the potential to high-
light physical regions that harbor putative disease associ-
ated variants for further re-sequencing to uncover ethnic-
specific disease associated variants.
Conclusion
Despite the inconsistencies in the epidemiological litera-
ture and inconclusiveness of current experimental obser-
vations on the role of aromatase in breast carcinogenesis,
a combination of experimental [13-17], laboratory [4,18-
22] and clinical data [3,23-27] strongly suggests a role for
aromatase in the etio-pathological network of breast car-
cinogenesis. Our finding of a modest increased risk of
breast cancer among women harboring 10 or more
(TTTA)n repeat alleles of the CYP19 (aromatase) gene is in
keeping with this proposition. As mentioned previously,
some of the current epidemiological studies lack adequate
sample size to detect the low risk profile impacted by low-
penetrance alleles such as the STRP being considered in
this study and this may have affected our results. We hope
to further investigate the association between this poly-
morphism and other variants in the CYP19 gene by
recruiting more study participants. There is emerging con-
sensus that future molecular epidemiological studies
should focus more on polygenic models employing hap-
lotytpe-based techniques to properly assess the contribu-
tions of various low-penetrance genes acting in specificJournal of Carcinogenesis 2006, 5:12 http://www.carcinogenesis.com/content/5/1/12
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metabolic pathways such as estrogen biosynthesis and
metabolism pathway to disease risk. Such studies will
require large sample sizes and the collaborative efforts of
multi-center investigators. In addition, the combination
of high through-put genotyping techniques with emerg-
ing technologies including microarray and proteomic
technology will enhance our ability to further understand
the genetic factors involved in breast carcinogenesis.
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